(LEG) Leggett & Platt - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5246601075
Steel Wire, Innersprings, Foam, Seating Components, Flooring
Dividends
| Dividend Yield | 1.73% |
| Yield on Cost 5y | 0.61% |
| Yield CAGR 5y | -21.42% |
| Payout Consistency | 75.5% |
| Payout Ratio | 19.2% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 51.3% |
| Value at Risk 5%th | 68.3% |
| Relative Tail Risk | -19.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.23 |
| Alpha | -17.40 |
| CAGR/Max DD | -0.32 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.583 |
| Beta | 1.168 |
| Beta Downside | 1.460 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.81% |
| Mean DD | 49.02% |
| Median DD | 62.57% |
Description: LEG Leggett & Platt November 15, 2025
Leggett & Platt (NYSE: LEG) is a diversified manufacturer of engineered components that serves a broad range of end-markets, including bedding, automotive seating, aerospace, and office furniture. Its product portfolio spans steel rods, innersprings, specialty foams, hydraulic cylinders, and motion hardware, which are sold to OEMs, private-label mattress makers, big-box retailers, and industrial users across North America, Europe, China, and other regions.
Key operating metrics highlight the company’s scale and cyclical exposure: FY 2024 revenue reached $5.0 billion, with an operating margin of roughly 12 % and a free-cash-flow conversion of 85 %. LEG’s performance is tightly linked to housing-starts trends (a 5-% YoY decline in U.S. starts in Q3 2024) and consumer discretionary spending, while its automotive-seating segment benefits from rising vehicle-interior upgrade rates (≈ 3 % annual growth). The firm’s diversified geography and product mix help mitigate localized demand shocks, but a sustained rise in interest rates could pressure mattress and furniture demand.
For a deeper quantitative assessment, you may find ValueRay’s detailed valuation models useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (224.4m TTM) > 0 and > 6% of Revenue (6% = 250.4m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 1.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.92% (prev 12.67%; Δ 9.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 339.0m > Net Income 224.4m (YES >=105%, WARN >=100%) |
| Net Debt (1.20b) to EBITDA (496.1m) ratio: 2.42 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (140.2m) change vs 12m ago 1.59% (target <= -2.0% for YES) |
| Gross Margin 17.93% (prev 16.76%; Δ 1.17pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 114.2% (prev 117.5%; Δ -3.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.78 (EBITDA TTM 496.1m / Interest Expense TTM 77.7m) >= 6 (WARN >= 3) |
Altman Z'' 5.38
| (A) 0.26 = (Total Current Assets 1.71b - Total Current Liabilities 794.1m) / Total Assets 3.52b |
| (B) 0.64 = Retained Earnings (Balance) 2.25b / Total Assets 3.52b |
| (C) 0.10 = EBIT TTM 371.3m / Avg Total Assets 3.65b |
| (D) 0.87 = Book Value of Equity 2.22b / Total Liabilities 2.55b |
| Total Rating: 5.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 55.57
| 1. Piotroski 5.0pt |
| 2. FCF Yield 9.92% |
| 3. FCF Margin 6.70% |
| 4. Debt/Equity 1.71 |
| 5. Debt/Ebitda 2.42 |
| 6. ROIC - WACC (= 6.27)% |
| 7. RoE 27.49% |
| 8. Rev. Trend -96.75% |
| 9. EPS Trend -86.00% |
What is the price of LEG shares?
As of December 14, 2025, the stock is trading at USD 11.59 with a total of 2,125,641 shares traded.
Over the past week, the price has changed by +3.76%, over one month by +28.63%, over three months by +21.23% and over the past year by +2.84%.
Over the past week, the price has changed by +3.76%, over one month by +28.63%, over three months by +21.23% and over the past year by +2.84%.
Is LEG a buy, sell or hold?
Leggett & Platt has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold LEG.
- Strong Buy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LEG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11 | -5.1% |
| Analysts Target Price | 11 | -5.1% |
| ValueRay Target Price | 10.4 | -10% |
LEG Fundamental Data Overview December 03, 2025
Market Cap USD = 1.62b (1.62b USD * 1.0 USD.USD)
P/E Trailing = 7.4161
P/S = 0.3875
P/B = 1.4299
P/EG = -4.11
Beta = 0.777
Revenue TTM = 4.17b USD
EBIT TTM = 371.3m USD
EBITDA TTM = 496.1m USD
Long Term Debt = 1.50b USD (from longTermDebt, last quarter)
Short Term Debt = 47.7m USD (from shortTermDebt, last quarter)
Debt = 1.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.20b USD (from netDebt column, last quarter)
Enterprise Value = 2.82b USD (1.62b + Debt 1.66b - CCE 460.7m)
Interest Coverage Ratio = 4.78 (Ebit TTM 371.3m / Interest Expense TTM 77.7m)
FCF Yield = 9.92% (FCF TTM 279.6m / Enterprise Value 2.82b)
FCF Margin = 6.70% (FCF TTM 279.6m / Revenue TTM 4.17b)
Net Margin = 5.38% (Net Income TTM 224.4m / Revenue TTM 4.17b)
Gross Margin = 17.93% ((Revenue TTM 4.17b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 18.69% (prev 17.86%)
Tobins Q-Ratio = 0.80 (Enterprise Value 2.82b / Total Assets 3.52b)
Interest Expense / Debt = 1.11% (Interest Expense 18.5m / Debt 1.66b)
Taxrate = 17.62% (27.2m / 154.4m)
NOPAT = 305.9m (EBIT 371.3m * (1 - 17.62%))
Current Ratio = 2.15 (Total Current Assets 1.71b / Total Current Liabilities 794.1m)
Debt / Equity = 1.71 (Debt 1.66b / totalStockholderEquity, last quarter 971.8m)
Debt / EBITDA = 2.42 (Net Debt 1.20b / EBITDA 496.1m)
Debt / FCF = 4.30 (Net Debt 1.20b / FCF TTM 279.6m)
Total Stockholder Equity = 816.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.37% (Net Income 224.4m / Total Assets 3.52b)
RoE = 27.49% (Net Income TTM 224.4m / Total Stockholder Equity 816.1m)
RoCE = 16.06% (EBIT 371.3m / Capital Employed (Equity 816.1m + L.T.Debt 1.50b))
RoIC = 11.82% (NOPAT 305.9m / Invested Capital 2.59b)
WACC = 5.55% (E(1.62b)/V(3.28b) * Re(10.32%) + D(1.66b)/V(3.28b) * Rd(1.11%) * (1-Tc(0.18)))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.35%
[DCF Debug] Terminal Value 70.32% ; FCFE base≈266.3m ; Y1≈265.1m ; Y5≈278.8m
Fair Price DCF = 25.20 (DCF Value 3.41b / Shares Outstanding 135.4m; 5y FCF grow -1.12% → 3.0% )
EPS Correlation: -86.00 | EPS CAGR: -22.93% | SUE: -0.69 | # QB: 0
Revenue Correlation: -96.75 | Revenue CAGR: -6.49% | SUE: 0.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=1.09 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+3.9% | Growth Revenue=-3.8%
P/E Trailing = 7.4161
P/S = 0.3875
P/B = 1.4299
P/EG = -4.11
Beta = 0.777
Revenue TTM = 4.17b USD
EBIT TTM = 371.3m USD
EBITDA TTM = 496.1m USD
Long Term Debt = 1.50b USD (from longTermDebt, last quarter)
Short Term Debt = 47.7m USD (from shortTermDebt, last quarter)
Debt = 1.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.20b USD (from netDebt column, last quarter)
Enterprise Value = 2.82b USD (1.62b + Debt 1.66b - CCE 460.7m)
Interest Coverage Ratio = 4.78 (Ebit TTM 371.3m / Interest Expense TTM 77.7m)
FCF Yield = 9.92% (FCF TTM 279.6m / Enterprise Value 2.82b)
FCF Margin = 6.70% (FCF TTM 279.6m / Revenue TTM 4.17b)
Net Margin = 5.38% (Net Income TTM 224.4m / Revenue TTM 4.17b)
Gross Margin = 17.93% ((Revenue TTM 4.17b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 18.69% (prev 17.86%)
Tobins Q-Ratio = 0.80 (Enterprise Value 2.82b / Total Assets 3.52b)
Interest Expense / Debt = 1.11% (Interest Expense 18.5m / Debt 1.66b)
Taxrate = 17.62% (27.2m / 154.4m)
NOPAT = 305.9m (EBIT 371.3m * (1 - 17.62%))
Current Ratio = 2.15 (Total Current Assets 1.71b / Total Current Liabilities 794.1m)
Debt / Equity = 1.71 (Debt 1.66b / totalStockholderEquity, last quarter 971.8m)
Debt / EBITDA = 2.42 (Net Debt 1.20b / EBITDA 496.1m)
Debt / FCF = 4.30 (Net Debt 1.20b / FCF TTM 279.6m)
Total Stockholder Equity = 816.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.37% (Net Income 224.4m / Total Assets 3.52b)
RoE = 27.49% (Net Income TTM 224.4m / Total Stockholder Equity 816.1m)
RoCE = 16.06% (EBIT 371.3m / Capital Employed (Equity 816.1m + L.T.Debt 1.50b))
RoIC = 11.82% (NOPAT 305.9m / Invested Capital 2.59b)
WACC = 5.55% (E(1.62b)/V(3.28b) * Re(10.32%) + D(1.66b)/V(3.28b) * Rd(1.11%) * (1-Tc(0.18)))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.35%
[DCF Debug] Terminal Value 70.32% ; FCFE base≈266.3m ; Y1≈265.1m ; Y5≈278.8m
Fair Price DCF = 25.20 (DCF Value 3.41b / Shares Outstanding 135.4m; 5y FCF grow -1.12% → 3.0% )
EPS Correlation: -86.00 | EPS CAGR: -22.93% | SUE: -0.69 | # QB: 0
Revenue Correlation: -96.75 | Revenue CAGR: -6.49% | SUE: 0.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=1.09 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+3.9% | Growth Revenue=-3.8%
Additional Sources for LEG Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle